STOK - Company ID 0001623526
The table below shows Stoke Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $184.42M | $36.55M | $8.78M | $12.40M | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $137.92M | $89.13M | $82.23M | $77.84M | $54.17M | $32.20M |
| SG&A |
Stoke Therapeutics, Inc. reported annual revenue of $184.42M for fiscal year 2025. That is up 404.5% from $36.55M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $67.09M |
| $48.79M |
| $41.32M |
| $38.92M |
| $31.90M |
| $20.85M |
| Operating income | -$20.59M | -$101.37M | -$114.77M | -$104.36M | -$86.06M | -$53.04M |
| Income tax | $0.00 | - | - | - | - | - |
| Net income | -$6.88M | -$88.98M | -$104.70M | -$101.07M | -$85.81M | -$52.24M |
| EPS (diluted) | -$0.12 | -$1.65 | -$2.38 | -$2.60 | -$2.34 | - |